TFs and related regulators x CaM

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs -- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis B virus (HBV) and hepatitis D virus (HDV) pipeline programs at the 2023 International HBV Meeting taking place in Kobe, Japan, September 19-23, 2023. At the meeting, one oral presentation will highlight progress in the company’s HBV/HDV oral entry inhibitor program including activity, selectivity and pharmacokinetic (PK) data that support advancement towards development candidate nomination. A second oral presentation reports new data for ABI-4334 (4334), Assembly Bio’s most potent capsid assembly modulator (CAM) with a potential best-in-class profile, describing the prevention of HBV DNA integration in vitro. The poster presentation, from the company’s interferon-α receptor (IFNAR) agonist program, characterizes small molecule IFNAR agonists that closely mimic interferon-α’s signaling. “The data we are presenting at the 2023 International HBV Meeting highlight the exciting progress of our preclinical HBV/HDV entry and IFNAR agonist programs, and we anticipate nominating a development candidate from the HBV/HDV entry inhibitor program this year,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “Further, the data reported for 4334 support its potential to prevent HBV DNA integration, a process that has been linked to substantial genetic damage and the development of liver cancer in HBV patients. HBV DNA integration is a pathogenic process that is not directly addressed by nucleos(t)ide analogs and further supports the rationale of targeting the viral core protein through a new class of inhibitors.” HBV/HDV Entry Inhibitor Program HDV is a satellite virus only found in the presence of HBV infection and is considered the most severe form of viral hepatitis. In an oral presentation entitled “Pre-clinical profiling of a novel class of orally bioavailable small molecules potently inhibiting hepatitis B and D virus entry,” the company will present data on a novel class of highly potent, orally bioavailable HBV/HDV entry small molecule inhibitors with favorable drug-like properties. One compound selected for further characterization exhibited potent activity against multiple HBV and HDV genotypes and selective inhibition of sodium taurocholate co-transporting polypeptide (NTCP) compared to other bile acid transporters. This compound further exhibited a favorable PK/pharmacodynamic preclinical pro the potential for once daily dosing. Assembly Bio anticipates nominating a clinical development candidate from the HBV/HDV entry inhibitor program in 2023. Next-Generation HBV CAM Candidate ABI-4334 4334, which has completed Phase 1a evaluation, is a novel, orally bioavailable investigational next-generation CAM that exhibits nanomolar (nM) potency against pgRNA encapsidation and covalently closed circular (ccc)DNA formation in vitro. In patients with chronic HBV infection, HBV DNA integration has been linked to the development of liver cancer. In the oral presentation entitled “ABI-4334, a novel inhibitor of hepatitis B virus core protein, disrupts DL-DNA containing capsids and prevents HBV DNA integration,” data show that in vitro 4334 disrupts RC (relaxed circular)- and DL (duplex linear)-DNA capsid formation at nM levels and inhibits HBV DNA integration in a dose-proportional manner as shown by inverse PCR and next-generation sequencing analyses​. Based on the Phase 1a PK data, the target plasma levels of 4334 required for inhibition of HBV DNA integration in these models are achievable. Interferon-α Receptor Agonist Assembly Bio’s IFNAR agonist program seeks to engage IFNα signaling using an orally bioavailable liver-focused small molecule approach to improve tolerability. The poster entitled “Pre-clinical characterization of novel liver-focused small molecules efficiently inhibiting hepatitis B virus by activating type I interferon signaling,” features preclinical data on a novel class of IFNAR agonists that inhibit HBV infection and replication. In vivo analysis of a compound from the series demonstrates that it closely mimics IFNα activity as measured by activating IFN-stimulated response element signaling and inducing the JAK-STAT pathway in the liver and PBMCs. PK data from the same compound exhibit desirable liver exposure and favorable oral bioavailability. Lead optimization of multiple IFNAR agonists is ongoing. Time and location of the presentations are as follows: HBV/HDV Entry Inhibitor: Oral Presentation: Pre-clinical profiling of a novel class of orally bioavailable small molecules potently inhibiting hepatitis B and D virus entry Presenter: Marc P. Windisch, PhD, Assembly Bio Session: Session IV: Drug discovery in preclinical models Date and Time: September 20, 3:30-5:15 PM JST ABI-4334: Oral Presentation: ABI-4334, a novel inhibitor of hepatitis B virus core protein, disrupts DL-DNA containing capsids and prevents HBV DNA integration Presenter: Nuruddin Unchwaniwala, PhD, Assembly Bio Session: Session VIIII: Integration, pathogenesis, and HCC Date and Time: September 22, 11 AM-1 PM JST Interferon-α Receptor Agonist: Poster Presentation: Pre-clinical characterization of novel liver-focused small molecules efficiently inhibiting hepatitis B virus by activating type I interferon signaling Presenter: Marc P. Windisch, PhD, Assembly Bio Session: Session IV: Drug discovery in preclinical models Date and Time: September 20, 5:15-7:15 PM JST Assembly Bio intends to make the presentations available on the “Events & Presentations” page in the “Investors” section of its website at About Assembly Biosciences Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor and Corporate: Shannon Ryan SVP, Investor Relations, Corporate Affairs and Alliance Management (415) 738-2992 sryan@assemblybio.com Media: Sam Brown Inc. Hannah Hurdle (805) 338-4752 ASMBMedia@sambrown.com

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center. Data is being presented for ALG-055009, Aligos’ THR-β agonist in clinical development for nonalcoholic steatohepatitis (NASH), as well as for several clinical and nonclinical stage investigational agents from its chronic hepatitis B (CHB) portfolio. “At this year’s meeting, we look forward to sharing data demonstrating that ALG-055009, our thyroid hormone receptor-beta (THR-β) agonist in development for NASH, showed promising anti-lipid effects in subjects with hyperlipidemia,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “In addition, we have several presentations which demonstrate the potentially best-in-class antiviral activity of our CAM-E compound, ALG-000184, where notable reductions in HBsAg levels have been observed with higher and longer-term dosing in subjects with HBeAg-positive CHB.” Presentation details, including summaries of data presented, follow below. Posters will be available for viewing throughout the conference for attendees and are also available on Aligos’ corporate website’s Scientific Presentations & Conferences page. NASH program Poster presentation Title: Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with HyperlipidaemiaPresenter: Hakim Charfi, M.D., Medical Director, Biotrial, FrancePoster number: PH-025Summary: Single ascending oral doses of ALG-055009 up to 4 mg in healthy volunteers as well as multiple doses up to 1 mg for 14 days in subjects with hyperlipidemia were generally well tolerated and were not associated with clinically significant changes in thyroid hormones or cardiovascular parameters. Additionally, ALG-055009 demonstrated favorable pharmacokinetics and anti-lipid effects with dose-proportional increases in exposure. Chronic hepatitis B program Oral presentations Title: The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALTPresenter: Professor Ed Gane, MBChB, M.D., University of Auckland, New ZealandPresentation date/time: Thursday, February 16, 14:40 – 14:55 Taipei Standard Time (TST)Presentation location: 3F North LoungeSession title: HBV (Clinical) and HCVPresentation number: FP03-16Summary: Oral daily dosing with 10 – 300 mg of ALG-000184 for 28 days resulted in substantial declines in HBV DNA and RNA at all doses, regardless of whether subjects were HBeAg-positive or negative. HBsAg declines as high as 0.78 log10 IU/mL were seen in subjects achieving drug exposures corresponding to 300 mg for 28 days. Title: ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B InfectionPresenter: Professor Jinlin Hou, M.D., Nanfang Medical University, Guangzhou, ChinaPresentation date/time: Thursday, February 16, 14:55 – 15:10 TSTPresentation location: 3F North LoungeSession title: HBV (Clinical) and HCVPresentation number: FP03-17Summary: In untreated subjects with CHB who were HBeAg-positive, ALG-000184 combined with entecavir (compared to entecavir alone) demonstrated superior antiviral activity as measured by HBV DNA and RNA reductions, as well as superior reductions in HBsAg, particularly in the 300 mg arm. These data demonstrate that ALG-000184 has best-in-class properties and a potential role in combination therapeutic regimens for CHB. Title: Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBVPresenter: Jin Hong, Ph.D., Aligos TherapeuticsPresentation date/time: Saturday, February 18, 11:35 – 11:50 TSTPresentation location: 3F South LoungeSession title: HBV (Basic)Presentation number: FP11-59Summary: Aligos’ Phase 1-stage siRNA candidate in development for chronic hepatitis B was designed using proprietary chemistries and exclusively licensed liver-targeting technology that may confer safety, stability, and potency advantages relative to other siRNA products. A summary of the preclinical in vitro and in vivo potency, efficacy and safety of ALG-125755 will be presented. Poster presentations Title: Effect of the Capsid Assembly Modulator (CAM) ALG-000184 on HBsAg Levels in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)Presenter: Professor Jinlin Hou, Nanfang Medical University, Guangzhou, ChinaPoster number: PC-019Summary: In subjects with CHB who were HBeAg-positive, oral daily dosing for 28 days with 100 mg and 300 mg of ALG-000184 yielded rapid and profound declines in HBV DNA and RNA. Additionally, subjects achieving drug exposures corresponding to 300 mg for 28 days demonstrated HBsAg declines up to 0.78 log10 IU/mL. Title: Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG-001075Presenter: Andreas Jekle, Ph.D., Aligos TherapeuticsPoster number: PB-007Summary: The capsid assembly modulator ALG-001075 (of which Aligos’ CAM-E candidate ALG-000184 is a prodrug) demonstrated potent antiviral activity in cell-based assays and in a mouse model. In primary human hepatocytes, ALG-001075 was shown to functions via both mechanisms that CAMs can engage: inhibiting the encapsidation of pregenomic RNA (pgRNA) and preventing the formation of covalently closed circular DNA (cccDNA). Title: Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA (siRNA), in Healthy Volunteers (HV)Presenter: Professor Ed Gane, MBChB, M.D., Auckland University, New ZealandPoster number: PPB-043Summary: In healthy volunteers, single doses of up to 200 mg of Aligos’ siRNA candidate ALG-125755 were well tolerated, and exposures increased dose-proportionally. A dose range that is predicted to achieve antiviral activity in CHB patients has been identified, at 40 – 100 mg. Title: Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver CancerPresenter: Heleen Roose, Ph.D., Aligos TherapeuticsPoster number: PB-010Summary: Aligos’ small molecule liver-targeted PD-L1 inhibitor, ALG-093702, was shown to block the PD-1/PD-L1 interaction while reducing cell surface PD-L1. The compound also demonstrated similar potency to the PD-L1 antibody drug durvalumab. ALG-093702’s potential to mitigate immune-related systemic toxicity makes it a candidate for use in CHB or other indications in the liver. About AligosAligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos is leveraging its expertise in liver and infectious diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH) and for the discovery and development of targeted antiviral therapies for coronaviruses. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and infectious disease, to rapidly advance its pipeline of potentially best-in-class molecules. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements that ALG-055009 is showing promising anti-lipid effects in subjects with hyperlipidemia and statements that with respect to Aligos’ CAM-E, ALG-000184, notable reductions in HBsAg levels have been observed with higher and longer-term dosing in subjects with HBeAg positive CHB. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic and the ongoing conflict between Russia and Ukraine. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Media ContactAmy Jobe, Ph.D.LifeSci Communications+1 315 879 8192ajobe@lifescicomms.com Investor ContactCorey Davis, Ph.D.LifeSci Advisors+1 212 915 2577cdavis@lifesciadvisors.com

ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster presentations also collectively highlight new data from the company’s drug candidates targeting PD-L1 inhibition and the CAM-A (CAM-aberrant) mechanism for the treatment of chronic hepatitis B (CHB) SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company is presenting several posters and an oral presentation at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD). Notably, poster 2354 provides new data on the activity of ALG-055009, Aligos’ thyroid hormone receptor beta (THR-β) agonist in development for nonalcoholic steatohepatitis (NASH). Multiple ascending dose (MAD) data from the ongoing Phase 1 study ALG-055009-301 (NCT05090111) demonstrate that treatment for 14 days in subjects with hyperlipidemia resulted in reduced triglyceride, low-density lipoprotein (LDL), and apolipoprotein B levels in a generally dose-dependent manner. ALG-055009 was well tolerated and resulted in favorable dose-proportional pharmacokinetics with low inter-subject variability across the therapeutic range. “We are pleased with the emerging clinical profile of ALG-055009,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “THR-β agonists continue to have the potential to become a cornerstone therapy in the treatment of NASH and ALG-055009 appears to benchmark favorably with other drugs in this class. Moving forward, we plan to evaluate its ability to reduce fat in the livers of subjects with NASH over a twelve-week period in a Phase 2 study funded internally or through a partnership.” Aligos’ oral and poster presentations at The Liver Meeting collectively highlight new data from the company’s drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) and are available on the Aligos website at Scientific Presentations & Conferences. Presentation details are described below. Aligos has highlighted new Phase 1 clinical data on its CAM-E drug candidate, ALG-000184, in a separate press release. Presentation Details NASH THR-β agonist Title: Safety, Pharmacokinetics, and Pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidaemic subjects Publication Number: 2354Presenter: Hakim Charfi, M.D. Summary: See above. Chronic Hepatitis B PD-L1 inhibitor: small molecule Title: Discovery of liver-targeted oral PDL1 small molecule inhibitors for the treatment of chronic hepatitis B and liver cancers Presentation Number: 34890Publication Number: 26Presenter: Tongfei Wu, Ph.D.Summary: The authors rationally designed liver-targeted oral PD-L1 small molecule inhibitors to localize T cell activation in the liver and thereby potentially mitigate systemic toxicity, toward an effort to develop better tolerated PD1/PD-L1 inhibitors for CHB patients. Lead molecules developed to date show similar in vivo efficacy to approved antibodies, but were more efficacious than antibodies in a liver metastatic tumor model. PD-L1 inhibitor: siRNA Title: Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV Poster Number: 36189Publication number: 1186Presenter: Jin Hong, Ph.D.Summary: Liver-targeted PD-L1 siRNA therapy may lead to restoration of immune responses against HBV and consequent clearance of HBV infection, which is considered critical for CHB cure. Multiple siRNAs with sub-nanomolar PD-L1 mRNA inhibition EC50 values have been identified. Efforts to identify siRNAs with greater PD-L1 expression knockdown efficiency as well as greater anti-HBV activity are ongoing. CAM-A Title: Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action Poster Number: 37007Publication number: 1208Presenter: Yannick Debing, Ph.D.Summary: Non-HAP (heteroaryldihydropyrimidine) CAM-1 (CAM-A, or CAM-aberrant) compounds ALG-005398 and ALG-006162 have a profile that is clearly distinct from known HAP CAM-1s. Data presented here suggest that non-HAP CAM-1s can promote HBsAg reduction via a mechanism distinct from that of HAP CAM-1s. As optimized non-HAP CAM-1s have suitable ADME/toxicity profiles, they represent an attractive class of molecules for further development as a part of potential functional cure regimens for CHB. Title: HAP Class I capsid assembly modulators clear hepatitis B virus-infected hepatocytes through core-dependent hepatocyte death and subsequent proliferation Poster Number: 36810Publication Number: 1202Presenter: Dieudoneé Buh Kum, Ph.D.Summary: In vivo and in vitro HAP CAM-1 (CAM-A, or CAM-aberrant) RG7907 was shown to act through two mechanisms, possibly complemented by an immune response, that result in a sustained loss of HBV-positive cells. First, RG7907 was shown to induce hepatitis B virus (HBV) core protein (HBc) aggregation and hepatocyte apoptosis in HBc-expressing cells. Second, compensatory hepatocyte proliferation was shown to lead to an additional loss of AAV-HBV episomes. This represents an attractive mechanism for regimens intended to introduce functional cure in CHB. siRNA Title: Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG-125755, a GaINAc-conjugated siRNA, for functional cure of chronic hepatitis B Poster Number: 35097Publication Number: 1155Presenter: Kusum Gupta Summary: ALG-125755 demonstrates encouraging preclinical pharmacology, PK/PD properties, and a long half-life in the liver, which predicts monthly or less frequent dosing in human subjects. A Phase 1 study of ALG-125755 began dosing in healthy volunteers in Oct 2022. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding THR-β agonists continuing to have the potential to become a cornerstone therapy in the treatment of NASH; ALG-055009 appearing to benchmark favorably with other drugs in this class and our plan to evaluate its ability to reduce fat in the livers of subjects with NASH over a twelve-week period in a Phase 2 study funded internally or through a partnership. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic and the ongoing conflict between Russia and Ukraine. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Media ContactAmy Jobe, Ph.D.LifeSci Communications+1 315 879 8192ajobe@lifescicomms.com Investor ContactCorey Davis, Ph.D.LifeSci Advisors+1 212 915 2577cdavis@lifesciadvisors.com